Cargando…

Fasting Insulin and Risk of Overall and 14 Site-Specific Cancers: Evidence From Genetic Data

OBJECTIVE: Whether fasting insulin (FI) plays a role in cancer risk remains unclear. This study aimed to investigate the association between FI and cancer risk and to explore its potential mediator role in the association between type 2 diabetes mellitus (T2DM) and cancer. METHODS: Two-sample Mendel...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Han, Li, Doudou, Liu, Xiaozhuan, Wan, Zhongxiao, Yu, Zengli, Wang, Yuming, Li, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069016/
https://www.ncbi.nlm.nih.gov/pubmed/35530326
http://dx.doi.org/10.3389/fonc.2022.863340
_version_ 1784700346042417152
author Zhang, Han
Li, Doudou
Liu, Xiaozhuan
Wan, Zhongxiao
Yu, Zengli
Wang, Yuming
Li, Xue
author_facet Zhang, Han
Li, Doudou
Liu, Xiaozhuan
Wan, Zhongxiao
Yu, Zengli
Wang, Yuming
Li, Xue
author_sort Zhang, Han
collection PubMed
description OBJECTIVE: Whether fasting insulin (FI) plays a role in cancer risk remains unclear. This study aimed to investigate the association between FI and cancer risk and to explore its potential mediator role in the association between type 2 diabetes mellitus (T2DM) and cancer. METHODS: Two-sample Mendelian randomization (TSMR) analysis was performed to evaluate the effect of FI on overall and 14 site-specific cancers using genome-wide association study (GWAS) summary-level data from Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) and consortia of 14 site-specific cancers. The primary MR approach was conducted by using the random-effect inverse-variance weighted (IVW) method, and sensitivity analyses were implemented by adopting weighted-median, weighted-mode, MR-Egger, and MR-PRESSO tests. Polygenic risk score analysis was executed by using individual-level data from UK Biobank to validate the findings from TSMR analyses. Multivariable Mendelian randomization (MVMR) was carried out to estimate the mediation effect of FI on the association between T2DM and cancer. RESULTS: TSMR study suggested that genetically determined high FI levels were associated with increased risk of colorectal cancer (odds ratio (OR) = 1.87, 95% CI: 1.23–2.84, p = 0.003) and endometrial cancer (OR = 1.89, 95% CI: 1.08–3.01, p = 0.008), but not associated with overall cancer risk or the other 12 studied cancer sites. Polygenic risk score analysis successfully replicated the association between genetic liability to high FI levels and the increased risk of colorectal and endometrial cancers. MVMR and MR mediation analyses detected an intermediary effect of FI and quantified that FI mediated 21.3% of the association between T2DM and endometrial cancer. CONCLUSIONS: This study demonstrated that FI levels are associated with the risk of colorectal and endometrial cancers, and FI was found to play an intermediary role in the association between T2DM and endometrial cancer. The associations between FI and other cancers need to be further studied.
format Online
Article
Text
id pubmed-9069016
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90690162022-05-05 Fasting Insulin and Risk of Overall and 14 Site-Specific Cancers: Evidence From Genetic Data Zhang, Han Li, Doudou Liu, Xiaozhuan Wan, Zhongxiao Yu, Zengli Wang, Yuming Li, Xue Front Oncol Oncology OBJECTIVE: Whether fasting insulin (FI) plays a role in cancer risk remains unclear. This study aimed to investigate the association between FI and cancer risk and to explore its potential mediator role in the association between type 2 diabetes mellitus (T2DM) and cancer. METHODS: Two-sample Mendelian randomization (TSMR) analysis was performed to evaluate the effect of FI on overall and 14 site-specific cancers using genome-wide association study (GWAS) summary-level data from Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) and consortia of 14 site-specific cancers. The primary MR approach was conducted by using the random-effect inverse-variance weighted (IVW) method, and sensitivity analyses were implemented by adopting weighted-median, weighted-mode, MR-Egger, and MR-PRESSO tests. Polygenic risk score analysis was executed by using individual-level data from UK Biobank to validate the findings from TSMR analyses. Multivariable Mendelian randomization (MVMR) was carried out to estimate the mediation effect of FI on the association between T2DM and cancer. RESULTS: TSMR study suggested that genetically determined high FI levels were associated with increased risk of colorectal cancer (odds ratio (OR) = 1.87, 95% CI: 1.23–2.84, p = 0.003) and endometrial cancer (OR = 1.89, 95% CI: 1.08–3.01, p = 0.008), but not associated with overall cancer risk or the other 12 studied cancer sites. Polygenic risk score analysis successfully replicated the association between genetic liability to high FI levels and the increased risk of colorectal and endometrial cancers. MVMR and MR mediation analyses detected an intermediary effect of FI and quantified that FI mediated 21.3% of the association between T2DM and endometrial cancer. CONCLUSIONS: This study demonstrated that FI levels are associated with the risk of colorectal and endometrial cancers, and FI was found to play an intermediary role in the association between T2DM and endometrial cancer. The associations between FI and other cancers need to be further studied. Frontiers Media S.A. 2022-04-21 /pmc/articles/PMC9069016/ /pubmed/35530326 http://dx.doi.org/10.3389/fonc.2022.863340 Text en Copyright © 2022 Zhang, Li, Liu, Wan, Yu, Wang and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhang, Han
Li, Doudou
Liu, Xiaozhuan
Wan, Zhongxiao
Yu, Zengli
Wang, Yuming
Li, Xue
Fasting Insulin and Risk of Overall and 14 Site-Specific Cancers: Evidence From Genetic Data
title Fasting Insulin and Risk of Overall and 14 Site-Specific Cancers: Evidence From Genetic Data
title_full Fasting Insulin and Risk of Overall and 14 Site-Specific Cancers: Evidence From Genetic Data
title_fullStr Fasting Insulin and Risk of Overall and 14 Site-Specific Cancers: Evidence From Genetic Data
title_full_unstemmed Fasting Insulin and Risk of Overall and 14 Site-Specific Cancers: Evidence From Genetic Data
title_short Fasting Insulin and Risk of Overall and 14 Site-Specific Cancers: Evidence From Genetic Data
title_sort fasting insulin and risk of overall and 14 site-specific cancers: evidence from genetic data
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069016/
https://www.ncbi.nlm.nih.gov/pubmed/35530326
http://dx.doi.org/10.3389/fonc.2022.863340
work_keys_str_mv AT zhanghan fastinginsulinandriskofoveralland14sitespecificcancersevidencefromgeneticdata
AT lidoudou fastinginsulinandriskofoveralland14sitespecificcancersevidencefromgeneticdata
AT liuxiaozhuan fastinginsulinandriskofoveralland14sitespecificcancersevidencefromgeneticdata
AT wanzhongxiao fastinginsulinandriskofoveralland14sitespecificcancersevidencefromgeneticdata
AT yuzengli fastinginsulinandriskofoveralland14sitespecificcancersevidencefromgeneticdata
AT wangyuming fastinginsulinandriskofoveralland14sitespecificcancersevidencefromgeneticdata
AT lixue fastinginsulinandriskofoveralland14sitespecificcancersevidencefromgeneticdata